There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Outset Medical (OM – Research Report), Exact Sciences (EXAS – Research Report) and DarioHealth (DRIO – Research Report) with bullish sentiments.
Outset Medical (OM)
In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Outset Medical, with a price target of $6.00. The company’s shares closed last Wednesday at $3.21, close to its 52-week low of $2.74.
According to TipRanks.com, Wise is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Outset Medical with a $6.38 average price target, which is a 95.1% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $9.00 price target.
See the top stocks recommended by analysts >>
Exact Sciences (EXAS)
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Exact Sciences today and set a price target of $100.00. The company’s shares closed last Wednesday at $63.29, close to its 52-week low of $58.37.
According to TipRanks.com, Arias has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $88.50, implying a 43.3% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock.
DarioHealth (DRIO)
Stifel Nicolaus analyst David Grossman maintained a Buy rating on DarioHealth today and set a price target of $4.00. The company’s shares closed last Wednesday at $2.03.
According to TipRanks.com, Grossman is a 5-star analyst with an average return of
Currently, the analyst consensus on DarioHealth is a Moderate Buy with an average price target of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OM:
